4investors 24 mai 2021 Abivax: Evotec-Partner meldet starke klinische Daten zu ABX464 bei Colitis ulcerosa
BioWorld 24 mai 2021 Abivax lining up pivotal program in ulcerative colitis as ABX-464 hits its marks in phase IIb study
Seeking Alpha 24 mai 2021 Abivax reports strong phase 2 data on ulcerative colitis candidate; shares up 12%
